Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 4/20 | 0.45 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.44 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.44 |
| ▸ | CASR | P41180 | 1/20 | 0.44 |
| ▸ | CTSS | P25774 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.42 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.42 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.41 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4841362 | 1.00 | ROCK2 (0.45) | ROCK2CYP4F2CYP4A11CASRCTSS | |
| SCHEMBL10070329 | 0.90 | CASR (0.44) | CYP4F2CYP4A11CASRCTSSCTSK | |
| SCHEMBL13802920 | 0.88 | CASR (0.45) | CASRCTSSCTSKLOXL2KDM4D | |
| SCHEMBL21510039 | 0.85 | ALDH1A1 (0.49) | ROCK2 | |
| SCHEMBL989453 | 0.84 | RIPK1 (0.42) | CYP4F2CYP4A11CTSSCTSKLOXL2 | |
| SCHEMBL30109148 | 0.84 | RIPK1 (0.42) | CYP4F2CYP4A11CTSSCTSKLOXL2 | |
| SCHEMBL3473488 | 0.83 | CTSK (0.45) | CYP4F2CYP4A11CASRCTSSCTSK | |
| SCHEMBL5575604 | 0.83 | CTSL (0.50) | CTSSCTSKRIPK1MAPT | |
| SCHEMBL16805929 | 0.83 | JAK2 (0.45) | ROCK2CTSSCTSKRIPK1GABRB1 | |
| SCHEMBL16690741 | 0.83 | CTSL (0.50) | CTSSCTSKRIPK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7351822-B2 | Serine protease inhibitors | ELI LILLY AND COMPANY (US) | 2008-04-01 | — | — | US | disclosed |
| US-7053078-B2 | Serine protease inhibitors | ELI LILLY AND COMPANY (US) | 2006-05-30 | — | — | US | disclosed |
| US-6946467-B2 | Serine protease inhibitors | ELI LILLY AND COMPANY (US) | 2005-09-20 | — | — | US | disclosed |
| EP-1289954-B1 | SERINE PROTEASE INHIBITORS | LILLY CO ELI (US) | 2005-09-14 | — | — | EP | disclosed |
| EP-1289953-B1 | SERINE PROTEASE INHIBITORS | LILLY CO ELI (US) | 2005-09-07 | — | — | EP | disclosed |
| US-6936611-B2 | Serine protease inhibitors | ELI LILLY AND COMPANY (US) | 2005-08-30 | — | — | US | disclosed |
| US-6900196-B2 | Serine protease inhibitors | ELI LILLY AND COMPANY (US) | 2005-05-31 | — | — | US | disclosed |
| US-6878725-B2 | Serine protease inhibitors | ELI LILLY AND COMPANY (US) | 2005-04-12 | — | — | US | disclosed |
| US-6878734-B2 | Gastrin and cholecystokinin receptor ligands(II) | JAMES BLACK FOUNDATION LIMITED (GB) | 2005-04-12 | — | — | US | disclosed |
| EP-1510515-A1 | Phenylglycine derivatives as serine protease inhibitors | ELI LILLY AND COMPANY (US) | 2005-03-02 | — | — | EP | disclosed |
| US-6784182-B2 | AND FACTOR XA INHIBITORS USEFUL IN THE TREATMENT OF CARDIOVASCULAR DISORDERS | ELI LILLY AND COMPANY | 2004-08-31 | — | — | US | disclosed |
| US-20040142963-A1 | Serine protease inhibitors | LIEBESCHUETZ JOHN WALTER (GB) | 2004-07-22 | — | — | US | disclosed |
| US-20030199565-A1 | Gastrin and cholecystokinin receptor ligands(II) | JAMES BLACK FOUNDATION LIMITED (GB) | 2003-10-23 | — | — | US | disclosed |
| US-20030109706-A1 | Serine pretease inhibitors | ELI LILLY AND COMPANY | 2003-06-12 | — | — | US | disclosed |
| US-20030078438-A1 | Serine protease inhibitors | ELI LILLY AND COMPANY | 2003-04-24 | — | — | US | disclosed |
| US-20030055246-A1 | Serine protease inhibitors | PROTHERICS MOLECULAR DESIGN LIMITED (GB) | 2003-03-20 | — | — | US | disclosed |
| EP-1289953-A1 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2003-03-12 | — | — | EP | disclosed |
| US-20020151724-A1 | Serine protease inhibitors | ELI LILLY AND COMPANY | 2002-10-17 | — | — | US | disclosed |
| WO-2001096304-A1 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
| WO-2001085723-A1 | GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS (II) | JAMES BLACK FOUNDATION LIMITED (GB) | 2001-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055246-A1 | Serine protease inhibitors | CTRL, CPN1, LOXL1 | ROCK2 4128/4885CYP4F2 2928/4885CYP4A11 1989/4885 |
| US-20030109706-A1 | Serine pretease inhibitors | PRSS1, SERPINE1, HPN | ROCK2 2919/4885CYP4F2 1645/4885CYP4A11 3182/4885 |
| US-20030078438-A1 | Serine protease inhibitors | HPN, LPXN, PRSS1 | ROCK2 1933/4885CYP4F2 1109/4885CYP4A11 2491/4885 |
| US-20040142963-A1 | Serine protease inhibitors | SERPINE1, PRSS1, SERPINB1 | ROCK2 2690/4885CYP4F2 1002/4885CYP4A11 1974/4885 |
| US-20020151724-A1 | Serine protease inhibitors | SERPINE1, PRSS1, SERPINB1 | ROCK2 2690/4885CYP4F2 1002/4885CYP4A11 1974/4885 |
| US-20030199565-A1 | Gastrin and cholecystokinin receptor ligands(II) | GRPR, CCKBR, GIPR | ROCK2 1498/4885CYP4F2 971/4885CYP4A11 641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.